MOEXIPRIL HYDROCHLORIDE tablet film coated

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

MOEXIPRIL HYDROCHLORIDE (UNII: Q1UMG3UH45) (MOEXIPRILAT - UNII:H3753190JS)

Disponível em:

Avera McKennan Hospital

DCI (Denominação Comum Internacional):

MOEXIPRIL HYDROCHLORIDE

Composição:

MOEXIPRIL HYDROCHLORIDE 7.5 mg

Tipo de prescrição:

PRESCRIPTION DRUG

Status de autorização:

Abbreviated New Drug Application

Características técnicas

MOEXIPRIL HYDROCHLORIDE- MOEXIPRIL HYDROCHLORIDE TABLET, FILM COATED
AVERA MCKENNAN HOSPITAL
----------
MOEXIPRIL HYDROCHLORIDE TABLETS
7.5 MG
RX ONLY
WARNING: FETAL TOXICITY
•
•
DESCRIPTION
Moexipril hydrochloride, the hydrochloride salt of moexipril, has the
empirical formula
C
H N O •HCl and a molecular weight of 535.04. It is chemically
described as [3S-
[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-
6,7-dimethoxy-3-isoquinolinecarboxylic acid, monohydrochloride. It is
a non-sulfhydryl containing
precursor of the active angiotensin-converting enzyme (ACE) inhibitor
moexiprilat and its structural
formula is:
Moexipril hydrochloride is a fine white to off-white powder. It is
soluble (about 10% weight-to-
volume) in distilled water at room temperature.
Moexipril hydrochloride is supplied as scored, coated tablets
containing 7.5 mg and 15 mg of moexipril
hydrochloride for oral administration. In addition to the active
ingredient, moexipril hydrochloride, the
tablet core contains the following inactive ingredients: crospovidone,
lactose monohydrate, magnesium
oxide, magnesium stearate and povidone. The film coating contains
hypromellose, hydroxypropyl
cellulose, titanium dioxide, polyethylene glycol 6000, magnesium
stearate, ferric oxide red, ferric
oxide black and ferric oxide yellow (15 mg tablet only).
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Moexipril hydrochloride is a prodrug for moexiprilat, which inhibits
ACE in humans and animals. The
mechanism through which moexiprilat lowers blood pressure is believed
to be primarily inhibition of
ACE activity. ACE is a peptidyl dipeptidase that catalyzes the
conversion of the inactive decapeptide
angiotensin I to the vasoconstrictor substance angiotensin II.
Angiotensin II is a potent peripheral
vasoconstrictor that also stimulates aldosterone secretion by the
adrenal cortex and provides negative
feedback on renin secretion. ACE is identical to kininase II, an
enzyme that degrades bradykinin, an
endothelium-depe